scholarly journals Meibomian gland dysfunction with involutional eyelids malposition

2016 ◽  
Vol 9 (1) ◽  
pp. 5-12 ◽  
Author(s):  
Vitaly V Potemkin ◽  
Vyacheslav V Rakhmanov ◽  
Elena V Ageeva ◽  
Aisa S Alchinova ◽  
Elena V Meshveliani
Keyword(s):  
International Workshop ◽  
Clinical Score ◽  
Lower Eyelid ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Control Group ◽  
Lack Of Information ◽  
Clinical Relationship ◽  
Eyelid Malposition ◽  
Meibomian Glands

The state of the ocular surface and visual functions depends on ocular adnexal tissues. Involutional changes of the eyelids and meibomian glands occur with age. There is a lack of information about possible relationship between involutional lower lid malposition and meibomian gland dysfunction. Purpose. To evaluate meibomian glands dysfunction in patients with lower eyelid malposition. Methods. Two groups of patients were enrolled: 26 patients (52 eyelids) with involutional lower eyelid malposition and a control group of 22 patients (44 eyelids) without eyelid malposition. Groups were comparable by age and sex. The clinical examination included general eye examination; evaluation of the degree of the eyelids laxity, signs of retractors dehiscence and clinical score of meibomian gland’s dysfunction (The International Workshop on Meibomian Gland Dysfunction, 2011). Results. Atonic eyelid changes and meibomian gland dysfunction were significantly more expressed in patients with involutional eyelid malposition (р < 0,05). Conclusion. Our study showed an age-independent clinical relationship between involutional lower eyelid malposition and dysfunction of meibomian glands.

scholarly journals Noncontact Meibography in Patients with Keratoconus

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Engy Mohamed Mostafa ◽  
Marwa Mahmoud Abdellah ◽  
Ashraf Mostafa Elhawary ◽  
Amr Mounir
Keyword(s):  
Morphological Changes ◽  
Tear Film ◽  
Cost Effective ◽  
Lower Eyelid ◽  
Meibomian Gland ◽  
Control Group ◽  
Schirmer Test ◽  
Ocular Surface Disease Index ◽  
Meibomian Glands ◽  
Grade 3

Purpose. To examine the morphological changes in the meibomian glands of patients with keratoconus as well as to study the relationship between these changes in the morphology and several tear film parameters. Methods. Examination of the meibomian gland (MG) of 300 keratoconus patients presenting to the center using infrared noncontact meibography system (Sirius, CSO, Italy) between January 2017—January 2019. 100 eyes of healthy individuals were also enrolled as a control group. Tear breakup time (TBUT) test and Schirmer test II were evaluated. Subjective symptoms were also assessed using Ocular Surface Disease Index (OSDI). Results. Mean age of keratoconus patients was 19 ± 12 years and 21 ± 14 years in control group. Average TBUT was 4.9 ± 2.1 sec. and average Schirmer test was 5.3 ± 2.2 mm which was significantly lower than control group (p=0.05). Meibomian gland dropout in the lower eyelid of the keratoconus group was as follows: grade 0 (no loss of meibomian glands): 100 eyes; grade 1 (gland dropout area <1/3 of the total meibomian glands): 85 eyes; grade 2 (gland dropout area 1/3 to 2/3): 68 eyes; and grade 3 (gland dropout >2/3): 47 eyes. Conclusion. Keratoconus shows significant meibomian gland dropout and distortion that can be recorded by noncontact meibography. Sirius meibography is a simple, cost-effective method of evaluating meibomian gland dropout as a part of the routine refractive examination.

Impression cytology and meibomian glands in conjunctivochalasis

2021 ◽  
pp. 112067212110087
Author(s):  
Ersin Muhafiz ◽  
Erdinç Bozkurt ◽  
Remzi Erten
Keyword(s):  
Dropout Rate ◽  
Meibomian Gland ◽  
Control Group ◽  
Study Group ◽  
Impression Cytology ◽  
Schirmer Test ◽  
Significant Difference ◽  
Meibomian Glands ◽  
And Control ◽  
Margin Cytology

Purpose: To evaluate the tear parameters, meibomian glands and lid margin and tarsal conjunctival impression cytology in patients with conjunctivochalasis (CCH). Methods: The study included 57 patients diagnosed with CCH and 35 healthy volunteers. Tear break-up time (TBUT) was measured and Schirmer test was performed. Meibomian gland morphologies, dropout rates, and meiboscores were evaluated using meibography. Finally, impression cytology samples were taken by pressing the impression filters on the lower lid margin and lower tarsal conjunctiva. The samples were evaluated according to the Nelson grading system. Results: Schirmer test was longer and TBUT was shorter in the study group ( p = 0.035 and p < 0.001, respectively). The median of meibomian gland dropout rate was 33.45% (Interquartile range [IQR]; 23.17%–49.75%) and 18.80% (IQR; 12.35%–26.50%) in the study and control groups, respectively ( p < 0.001). There was no significant difference in terms of lid-margin cytology between the two groups ( p = 0.481). In tarsal conjunctiva cytology, the median value of Nelson grade of the study group was 2 (IQR; 1–2) and that of the control group was 1 (IQR; 1–2) ( p = 0.040). When Nelson grade-2 and above was accepted as the pathological limit, it was found that 27.5% of the study group and 15.2% of the control group showed pathological findings ( p = 0.204). Conclusions: In patients with CCH, damage occurs in the tarsal conjunctiva with the effects of redundant conjunctival folds. In these patients, atrophy occurs in the meibomian glands and tear stability is impaired. Therefore, CCH should not be overlooked in clinical practice.

Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients

2021 ◽  
Author(s):  
Siyuan Li ◽  
Ke Yang ◽  
Jingyi Wang ◽  
Shang Li ◽  
Lei Zhu ◽  
...  
Keyword(s):  
Group Treatment ◽  
Controlled Trial ◽  
Anterior Segment ◽  
Meibomian Gland ◽  
Chinese Patients ◽  
Meibomian Gland Dysfunction ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Meibomian Glands ◽  
Thermostatic Device

Abstract BackgroundAs a chronic disease, meibomian gland dysfunction (MGD) which causes excessive evaporation of tears by changing the tear film composition, is considered a leading cause of dry eye. Although a variety of physical therapy equipment, there is currently no economical and effective treatment for MGD. The aim of this study was to evaluate the effectiveness and safety of the MiBoFlo Thermoflo® (Mibo Medical, Dallas, TX, USA), a new thermostatic device, on both objective symptoms and subjective signs in Chinese MGD patients.MethodsThis was a prospective, randomized, controlled clinical trial. 108 eyes of 54 MGD patients in Beijing Tongren Hospital were recruited and randomized 1:1 to MiBoFlo (n = 54 eyes) or LipiFlow® (TearScience, Morrisville, NC, USA) (n = 54 eyes) treatment group. In the MiBoFlo group, treatment for each eye took 10 minutes and proceeded every two weeks for a total of three times. Patients in the LipiFlow group received a single 12-minute treatment. Main Outcome Measures: The primary outcomes include changes in Ocular Surface Disease Index (OSDI) score, Meibomian Glands Yielding Liquid Secretion (MGYLS) score and Meibomian Glands Secretion (MGS) score from baseline to 2 months. The secondary outcomes include Tear Meniscus Height (TMH), Non-invasive Keratograph Break-up Time (NIKBUT), Corneal Fluorescein Staining (CFS) and Meibomian Glands (MG) loss from baseline to 2 months. Safety outcomes include visual acuity (VA), intraocular pressure (IOP), anterior segment and facial skin.ResultsThe OSDI score, MGYLS score and MGS score all improved from baseline to 1 month in both MiBoFlo and LipiFlow group, and these improvements were maintained at 2 months. CFS score, NIKBUT and MG loss had no significant change in both groups. CFS score improvement in MiBoFlo group were significantly more obvious than in LipiFlow group in the follow-up visit (p<0.01).ConclusionAs a portable and comfortable device, MiBoFlo treatment can offer an advancement for the treatment of MGD and a course of treatment results in at least two months of sustained improvement in both symptoms and meibomain gland function.

scholarly journals The International Workshop on Meibomian Gland Dysfunction: Executive Summary

2011 ◽  
Vol 52 (4) ◽  
pp. 1922 ◽  
Author(s):  
Kelly K. Nichols ◽  
Gary N. Foulks ◽  
Anthony J. Bron ◽  
Ben J. Glasgow ◽  
Murat Dogru ◽  
...  
Keyword(s):  
International Workshop ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Executive Summary

Noncontact Meibography Detects Changes in Meibomian Glands in the Aging Process in a Normal Population and Patients with Meibomian Gland Dysfunction

Cornea ◽  
2009 ◽  
Vol 28 (Suppl 1) ◽  
pp. S75-S79 ◽  
Author(s):  
Reiko Arita ◽  
Kozo Itoh ◽  
Kenji Inoue ◽  
Shuji Maeda ◽  
Koshi Maeda ◽  
...  
Keyword(s):  
Aging Process ◽  
Normal Population ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Meibomian Glands

scholarly journals Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and Severity

2020 ◽  
Vol 209 ◽  
pp. 160-167 ◽  
Author(s):  
Jiaxin Xiao ◽  
Muhammed Yasin Adil ◽  
Xiangjun Chen ◽  
Øygunn A. Utheim ◽  
Sten Ræder ◽  
...  
Keyword(s):  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Morphological Evaluation ◽  
Meibomian Glands

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

2022 ◽  
Vol 7 (4) ◽  
pp. 667-671
Author(s):  
Prajwalli Reddy ◽  
Wajeeha Umam
Keyword(s):  
Dry Eye ◽  
Cyclosporine A ◽  
Ocular Surface ◽  
Tear Film ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Control Group ◽  
Dry Eyes ◽  
Group A ◽  
Group B

: Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Meibomian Gland Dysfunction (MGD) is an abnormality of the meibomian gland that blocks the secretion of lipids. Without sufficient lipid production, tears evaporate quickly causing Dry Eye.MGD is associated with multiple pathological mechanisms including inflammation, microbial factors and lipid deficiencies. Topical Cyclosporine A (CsA) 0.05% is a calcineurin inhibitor that reduces inflammation by specifically inhibiting T‑cell activity, which reduces ocular surface inflammation and improves tear film dynamics. This was a prospective observational study done on 100 patients at the Department of Ophthalmology Basaveshwar teaching and general hospital, on patients of dry eyes due to meibomian gland dysfunction. Patients who were diagnosed with dry eyes due to meibomian gland dysfunction were invited to take part in the study. Patients were divided randomly into two groups of 50 patients each. This study, was explained in detail to them. An informed consent was obtained. Patients fulfilling the inclusion criteria were listed.All OSDI scores (symptom intensity, frequency and aggravation) revealed decreasing patterns throughout the observation period in both the groups. In single analysis, the cyclosporine A 0.05% group showed a significant improvement for each score at 3 months (p &#60; 0.01, p = 0.01, p = 0.02, respectively). The mean TBUT after treatment in the group A (cyclosporine A group) increased to 12.36± 3.58(p&#60;0.001) seconds, and in the group B (Control group) the TBUT score increased to 11.01±3.06 seconds. After 3 Months, there was statistically significant improvement in the mean Schirmer’s scores in both the treatment groups, however improvement was significantly greater in Cyclosporine A group. Prior to the treatment in group A (Cyclosporine A) mean Lissamine staining score was 2.73±0.15 and post treatment it reduced to 1.32±0.15 which was statistically significant (P&#60;0.001). In group B (Control group) score before treatment was 2.46±0.15 and after treatment it reduced to 2.39±0.27 (p=0.11), not much difference was seen. : Findings from our study showed that there were significant improvements in the dry eye conditions due to defect in meibomian gland by treatment of topical Cyclosporine A 0.05% and sodium hyaluronate 0.1%.

Focused ultrasound stimulation on meibomian glands for the treatment of evaporative dry eye

2021 ◽  
pp. 153537022110520
Author(s):  
Gengxi Lu ◽  
Sumanth Gollapudi ◽  
Runze Li ◽  
Margaret L Pfeiffer ◽  
Preeya Mehta ◽  
...  
Keyword(s):  
Layer Thickness ◽  
Dry Eye ◽  
Focused Ultrasound ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Lipid Layer ◽  
Mean Values ◽  
Ultrasound Stimulation ◽  
Evaporative Dry Eye ◽  
Meibomian Glands

Current treatments for meibomian gland dysfunction have several limitations, creating a necessity for other advanced treatment options. The purpose of this study is to determine the effectiveness of focused ultrasound stimulation for the treatment of dry eye disease caused by meibomian gland dysfunction. An in vivo study of nine Dutch Belted rabbits was conducted with focused ultrasound stimulation of the meibomian glands. A customized line-focused ultrasonic transducer was designed for treatment. Fluorescein imaging, Schirmer’s test, and Lipiview II ocular interferometer were used to quantify outcomes from three aspects: safety, tear production, and lipid layer thickness. Both tear secretion and lipid layer thickness improved following ultrasound treatment. Five to 10 min after the ultrasound treatment, the mean values of lipid layer thickness increased from 55.33 ± 11.15 nm to 95.67 ± 22.77 nm ( p < 0.05), while the mean values measured with the Schirmer’s test increased from 2.0 ± 2.3 to 7.2 ± 4.3 ( p < 0.05). Positive effects lasted more than three weeks. Adverse events such as redness, swelling, and mild burn, occurred in two rabbits in preliminary experiments when the eyelids sustained a temperature higher than 42°C. No serious adverse events were found. The results suggest that ultrasound stimulation of meibomian glands can improve both tear production and lipid secretion. Ultimately, ultrasound stimulation has the potential to be an option for the treatment of evaporative dry eye disease caused by meibomian gland dysfunction.

Sign in / Sign up

Export Citation Format

Share Document